Shepherd FA, Hirsh V, Smylie M, Findlay B, Santabárbara P. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353(2):123-32.
DOI: 10.1056/NEJMoa050753
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3):239-46.
DOI: 10.1016/S1470-2045(11)70393-X
Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013;24(1):54-9.
DOI: 10.1093/annonc/mds214
Sequist LV, Yang JCH, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol 2013;31(27):3327-34.
DOI: 10.1200/JCO.2012.44.2806
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18(11):1454-66.
DOI: 10.1016/S1470-2045(17)30608-3
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med 2018;378(2):113-25.
DOI: 10.1056/NEJMoa1713137
SEOM. Las cifras del cáncer en España 2023 [citado el 21 de junio de 2023]. Disponible en: https://seom.org/images/Las_cifras_del_Cancer_en_Espana_2023.pdf
Hsu WH, Yang JCH, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol 2018;29:i3-9.
DOI: 10.1093/annonc/mdx702
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8):735-42.
DOI: 10.1016/S1470-2045(11)70184-X
Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015;26(9):1883-9.
DOI: 10.1093/annonc/mdv270
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009;361(10):947-57.
DOI: 10.1056/NEJMoa0810699
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11(2):121-8.
DOI: 10.1016/S1470-2045(09)70364-X
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(25):2380-8.
DOI: 10.1056/NEJMoa0909530
Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13(5):528-38.
DOI: 10.1016/S1470-2045(12)70087-6
Ellis PM, Liu G, Millward M, Perrone F, Shepherd FA, Sun S, et al. NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. J Clin Oncol 2014;32(Suppl.15):8036-8036.
DOI: 10.1200/jco.2014.32.15_suppl.8036
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15(2):213-22.
DOI: 10.1016/S1470-2045(13)70604-1
Paz-Ares L, Tan EH, O’Byrne K, Zhang L, Hirsh V, Boyer M, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 2017;28(2):270-7.
DOI: 10.1093/annonc/mdw611
Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, et al. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. Cancers 2021;13(19):4926.
DOI: 10.3390/cancers13194926
Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Mechanisms of resistance to osimertinib. J Thorac Dis 2020;12(5):2851-8.
DOI: 10.21037/jtd.2019.08.30
Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, et al. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol 2020;31(11):1536-44.
DOI: 10.1016/j.annonc.2020.08.2100
Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol 2018;29(3):687-93.
DOI: 10.1093/annonc/mdx820
Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, et al. CNS Efficacy of Osimertinib in Patients with T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data from a Randomized Phase III Trial (AURA3). J Clin Oncol 2018;36(26):2702-9.
DOI: 10.1200/JCO.2018.77.9363
Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer. J Clin Oncol 2018;36(33):3290-7.
DOI: 10.1200/JCO.2018.78.3118
Hou J, Li H, Ma S, He Z, Yang S, Hao L, et al. EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives. Biomark Res 2022;10(1):21.
DOI: 10.1186/s40364-022-00372-6
Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol Off J Am Soc Clin Oncol 2021;39(30):3391-402.
DOI: 10.1200/JCO.21.00662
Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JCH, Riely GJ, et al. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol 2021;7(12):e214761.
DOI: 10.1001/jamaoncol.2021.4761
Wu SG, Shih JY. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Mol Cancer 2018;17(1):38.
DOI: 10.1186/s12943-018-0777-1
Santarpia M, Altavilla G, Borsellino N, Girlando A, Mancuso G, Pergolizzi S, et al. High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data In Vivo 2020;34(4):2009-14.
DOI: 10.21873/invivo.11999
Kim HS, Lim KY, Lee SH, Kim HY, Lee Y, Han JY. Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M-positive non-small cell lung cancer. Cancer Med [citado el 7 de junio de 2023];n/a(n/a). Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.5926
Wei B, Zhao C, Li J, Zhao J, Ren P, Yang K, et al. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example. Mol Oncol 2019;13(5):1226-34.
DOI: 10.1002/1878-0261.12481
Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Cancer Res Treat Off J Korean Cancer Assoc 2019;51(2):777-87.
DOI: 10.4143/crt.2018.387
Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, et al. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer. West Japan Oncology Group 8815L/LPS study. Cancer 2020;126(9):1940-1948.
DOI: 10.1002/cncr.32749
Maso AD, Lorenzi M, Roca E, Pilotto S, Macerelli M, Polo V, et al. Clinical Features and Progression Pattern of Acquired T790M-positive Compared with T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clin Lung Cancer 2020;21(1):1-14.e3.
DOI: 10.1016/j.cllc.2019.07.009
Bordi P, Re MD, Minari R, Rofi E, Buti S, Restante G, et al. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. Lung Cancer 2019;131:78-85.
DOI: 10.1016/j.lungcan.2019.03.017
Sakai K, Takahama T, Shimokawa M, Azuma K, Takeda M, Kato T, et al. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Mol Oncol 2021;15(1):126-37.
DOI: 10.1002/1878-0261.12841
Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, Bosch-Barrera J, et al. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Med 2021;10(17):5878-88.
DOI: 10.1002/cam4.4135
Osoegawa A, Yamaguchi M, Nakamura T, Morinaga R, Tanaka K, Kashiwabara K, et al. High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib. JTO Clin Res Rep 2021 [citado el 14 de junio de 2023];2(7). Disponible en: https://www.jtocrr.org/article/S2666-3643(21)00050-3/fulltext
DOI: 10.1016/j.jtocrr.2021.100191
Niederst MJ, Hu H, Mulvey HE, Lockerman EL, García AR, Piotrowska Z, et al. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res 2015;21(17):3924-33.
DOI: 10.1158/1078-0432.CCR-15-0560
Ariyasu R, Uchibori K, Sasaki T, Tsukahara M, Kiyotani K, Yoshida R, et al. Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR. Cancer Sci 2021;112(6):2371-80.
DOI: 10.1111/cas.14879
Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol 2019;12(1):134.
DOI: 10.1186/s13045-019-0818-2
Raphael A, Dudnik E, Hershkovitz D, Jain S, Olsen S, Soussan-Gutman L, et al. FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC). J Clin Med 2022;11(9):2475.
DOI: 10.3390/jcm11092475
Nguyen KT, Sakthivel G, Milano MT, Qiu H, Singh DP. Oligoprogression in non-small cell lung cancer: a narrative review. J Thorac Dis 2022;14(12):4998-5011.
DOI: 10.21037/jtd-22-536
Lim JU. Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors. Clin Lung Cancer 2021;22(5):e786-92.
DOI: 10.1016/j.cllc.2021.03.004
Li X yang, Zhu X ru, Zhang C chen, Yu W, Zhang B, Shen T le, et al. Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors. Clin Lung Cancer 2020;21(6):534-44.
DOI: 10.1016/j.cllc.2020.04.004
Merino Lara T, Helou J, Poon I, Sahgal A, Chung HT, Chu W, et al. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy? Lung Cancer 2018;124:219-26.
DOI: 10.1016/j.lungcan.2018.08.005
Jiang T, Chu Q, Wang H, Zhou F, Gao G, Chen X, et al. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. Int J Cancer 2019;144(10):2605-12.
DOI: 10.1002/ijc.31962
Hu C, Wu S, Deng R, Wu Y, Pan Y, Shu L, et al. Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study. Cancer Med 2022;12(1):266-73.
DOI: 10.1002/cam4.4894
Schmid S, Klingbiel D, Aeppli S, Britschgi C, Gautschi O, Pless M, et al. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer 2019;130:149-55.
DOI: 10.1016/j.lungcan.2019.02.020
Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, et al. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun 2019;19:100126.
DOI: 10.1016/j.ctarc.2019.100126
Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor with or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J Natl Cancer 2023;115(6):742-8.
DOI: 10.1093/jnci/djac015
Rossi S, Finocchiaro G, Noia VD, Bonomi M, Cerchiaro E, Rose FD, et al. Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Future Oncol 2019;15(33):3775-82.
DOI: 10.2217/fon-2019-0349
Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 2019;121(9):725-37.
DOI: 10.1038/s41416-019-0573-8
Shu CA, Goto K, Ohe Y, Besse B, Lee SH, Wang Y, et al. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. J Clin Oncol 2022;40(Suppl.16):9006-9006.
DOI: 10.1200/JCO.2022.40.16_suppl.9006
Yu HA, Ambrose H, Baik C, Cho BC, Cocco E, Goldberg SB, et al. 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. Ann Oncol 2021;32:S978-9.
DOI: 10.1016/j.annonc.2021.08.1844
Astrazeneca. Tagrisso plus savolitinib demonstrated 49 % objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial 2022 [citado el 19 de junio de 2023]. Disponible en: https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-plus-savolitinib-demonstrated-49-objective-response-rate-in-lung-cancer-patients-in-savannah-phase-ii-trial.html
Smit EF, Dooms C, Raskin J, Nadal E, Tho LM, Le X, et al. INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncol Lond Engl 2022;18(9):1039-54.
DOI: 10.2217/fon-2021-1406
Wang J, García Campelo R, Girard N, Leighl N, Reckamp K, Takahashi T, et al. 398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy frente a chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure. Ann Oncol 2022;33:S1597.
DOI: 10.1016/j.annonc.2022.10.500
Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, et al. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. J Thorac Oncol 2022;17(2):309-23.
DOI: 10.1016/j.jtho.2021.09.014
ASCO Daily News. Pembro Plus Chemo Fails to Show Efficacy Benefit in TKI-Resistant, EGFR-Mutated, Metastatic Nonsquamous NSCLC [citado el 19 de junio de 2023]. Disponible en: https://dailynews.ascopubs.org/do/pembro-plus-chemo-fails-show-efficacy-benefit-tki-resistant-egfr--mutated-metastatic
Número de descargas:
31895
Número de visitas:
729
Citas:
0
